Heart Disease Clinical Trials in Miami

Showing 61-80 of 256 trials

Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health

NCT06587204

The objective of the UDECIDE study is to demonstrate adherence to decentralized clinical trials among underrepresented groups with cardiometabolic conditions .

Heart Diseases

University of Miami125 participantsStarted Sep 2025

Miami, Florida, United States

COMPLETEDPhase 3< 1 mile

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

NCT04847557

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

ObesityHeart Failure With Preserved Ejection Fraction (HFpEF)

Eli Lilly and Company731 participantsStarted Apr 2021

Huntsville, Alabama, United States • Beverly Hills, California, United States • Covina, California, United States +143 more locations

Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Heart Disease Trials in Other Cities

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Study of JK07 in Patients With Chronic Heart Failure

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Hemodynamic-GUIDEd Management of Heart Failure

Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Abbott Vascular Medical Device Registry

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve

Other Conditions in Miami